PDCD1 and neoplasm: The preclinical study showed that treatment with a selective PI3Kβ small molecule inhibitor, GSK2636771, improved the efficacy of both anti-PD-1 and anti-CTLA-4 antibodies by enhancing the expansion of tumor-specific lymphocytes [119].